In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
New publication of a retrospective, observational study of Gelatin tannate versus other antidiarrheal medication in children with acute Gastroenteritis.
“A clinical trial recently published assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray (Rhinosectan) in the treatment of rhinosinusitis, and concluded that this medical device provided greater relief of symptoms than a physiological saline spray”. Allegrini A et al. A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis. Current Medical Research and Opinion, 2017. DOI: 0.1080/03007995.2017.1341402
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.
